Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function

Shannon P. Fortin, Matthew J. Ennis, Benjamin A. Savitch, David Carpentieri, Wendy S. McDonough, Jeffrey A. Winkles, Joseph C Loftus, Christopher Kingsley, Galen Hostetter, Nhan Tran

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and significant technical advances in surgical and radiation treatment, the impact on clinical outcome for patients with malignant gliomas is disappointing. We have previously shown that tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival via binding to the Fn14 receptor, activation of the NF-κB pathway, and upregulation of BCL-X L gene expression. Here, we show that TWEAK treatment of glioma cells leads to phosphorylation of Akt and BAD. TWEAK stimulation results in the phosphorylation of both Akt1 and Akt2. However, small interfering RNA (siRNA)-mediated depletion of either Akt1 or Akt2 showed that BAD serine 136 phosphorylation is dependent specifically on Akt2 function. Depletion of Akt2 expression by siRNA also abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival was observed after siRNA-mediated depletion of Akt1 expression. Surprisingly, although siRNA-mediated depletion of BAD in glioma cells abrogates cytotoxic- and chemotherapy-induced apoptosis, TWEAK still displays a strong protective effect, suggesting that BAD serine 136 phosphorylation plays a minor role in TWEAK-Akt2-induced glioma cell survival. We also report here that AKT2 gene expression levels increased with glioma grade and inversely correlate with patient survival. Additionally, immunohistochemical analysis showed that Akt2 expression positively correlates with Fn14 expression in glioblastoma multiforme specimens. We hypothesize that the TWEAK-Fn14 signaling axis functions, in part, to enhance glioblastoma cell survival by activation of the Akt2 serine/threonine protein kinase.

Original languageEnglish (US)
Pages (from-to)1871-1881
Number of pages11
JournalMolecular Cancer Research
Volume7
Issue number11
DOIs
StatePublished - Nov 2009

Fingerprint

Glioma
Cell Survival
Tumor Necrosis Factor-alpha
Apoptosis
Small Interfering RNA
Phosphorylation
Glioblastoma
Serine
Gene Expression
Protein-Serine-Threonine Kinases
Brain Neoplasms
Up-Regulation
Radiation
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. / Fortin, Shannon P.; Ennis, Matthew J.; Savitch, Benjamin A.; Carpentieri, David; McDonough, Wendy S.; Winkles, Jeffrey A.; Loftus, Joseph C; Kingsley, Christopher; Hostetter, Galen; Tran, Nhan.

In: Molecular Cancer Research, Vol. 7, No. 11, 11.2009, p. 1871-1881.

Research output: Contribution to journalArticle

Fortin, SP, Ennis, MJ, Savitch, BA, Carpentieri, D, McDonough, WS, Winkles, JA, Loftus, JC, Kingsley, C, Hostetter, G & Tran, N 2009, 'Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function', Molecular Cancer Research, vol. 7, no. 11, pp. 1871-1881. https://doi.org/10.1158/1541-7786.MCR-09-0194
Fortin, Shannon P. ; Ennis, Matthew J. ; Savitch, Benjamin A. ; Carpentieri, David ; McDonough, Wendy S. ; Winkles, Jeffrey A. ; Loftus, Joseph C ; Kingsley, Christopher ; Hostetter, Galen ; Tran, Nhan. / Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. In: Molecular Cancer Research. 2009 ; Vol. 7, No. 11. pp. 1871-1881.
@article{043ed8bfa6c7491e89c253d237f372ab,
title = "Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function",
abstract = "Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and significant technical advances in surgical and radiation treatment, the impact on clinical outcome for patients with malignant gliomas is disappointing. We have previously shown that tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival via binding to the Fn14 receptor, activation of the NF-κB pathway, and upregulation of BCL-X L gene expression. Here, we show that TWEAK treatment of glioma cells leads to phosphorylation of Akt and BAD. TWEAK stimulation results in the phosphorylation of both Akt1 and Akt2. However, small interfering RNA (siRNA)-mediated depletion of either Akt1 or Akt2 showed that BAD serine 136 phosphorylation is dependent specifically on Akt2 function. Depletion of Akt2 expression by siRNA also abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival was observed after siRNA-mediated depletion of Akt1 expression. Surprisingly, although siRNA-mediated depletion of BAD in glioma cells abrogates cytotoxic- and chemotherapy-induced apoptosis, TWEAK still displays a strong protective effect, suggesting that BAD serine 136 phosphorylation plays a minor role in TWEAK-Akt2-induced glioma cell survival. We also report here that AKT2 gene expression levels increased with glioma grade and inversely correlate with patient survival. Additionally, immunohistochemical analysis showed that Akt2 expression positively correlates with Fn14 expression in glioblastoma multiforme specimens. We hypothesize that the TWEAK-Fn14 signaling axis functions, in part, to enhance glioblastoma cell survival by activation of the Akt2 serine/threonine protein kinase.",
author = "Fortin, {Shannon P.} and Ennis, {Matthew J.} and Savitch, {Benjamin A.} and David Carpentieri and McDonough, {Wendy S.} and Winkles, {Jeffrey A.} and Loftus, {Joseph C} and Christopher Kingsley and Galen Hostetter and Nhan Tran",
year = "2009",
month = "11",
doi = "10.1158/1541-7786.MCR-09-0194",
language = "English (US)",
volume = "7",
pages = "1871--1881",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function

AU - Fortin, Shannon P.

AU - Ennis, Matthew J.

AU - Savitch, Benjamin A.

AU - Carpentieri, David

AU - McDonough, Wendy S.

AU - Winkles, Jeffrey A.

AU - Loftus, Joseph C

AU - Kingsley, Christopher

AU - Hostetter, Galen

AU - Tran, Nhan

PY - 2009/11

Y1 - 2009/11

N2 - Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and significant technical advances in surgical and radiation treatment, the impact on clinical outcome for patients with malignant gliomas is disappointing. We have previously shown that tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival via binding to the Fn14 receptor, activation of the NF-κB pathway, and upregulation of BCL-X L gene expression. Here, we show that TWEAK treatment of glioma cells leads to phosphorylation of Akt and BAD. TWEAK stimulation results in the phosphorylation of both Akt1 and Akt2. However, small interfering RNA (siRNA)-mediated depletion of either Akt1 or Akt2 showed that BAD serine 136 phosphorylation is dependent specifically on Akt2 function. Depletion of Akt2 expression by siRNA also abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival was observed after siRNA-mediated depletion of Akt1 expression. Surprisingly, although siRNA-mediated depletion of BAD in glioma cells abrogates cytotoxic- and chemotherapy-induced apoptosis, TWEAK still displays a strong protective effect, suggesting that BAD serine 136 phosphorylation plays a minor role in TWEAK-Akt2-induced glioma cell survival. We also report here that AKT2 gene expression levels increased with glioma grade and inversely correlate with patient survival. Additionally, immunohistochemical analysis showed that Akt2 expression positively correlates with Fn14 expression in glioblastoma multiforme specimens. We hypothesize that the TWEAK-Fn14 signaling axis functions, in part, to enhance glioblastoma cell survival by activation of the Akt2 serine/threonine protein kinase.

AB - Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and significant technical advances in surgical and radiation treatment, the impact on clinical outcome for patients with malignant gliomas is disappointing. We have previously shown that tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival via binding to the Fn14 receptor, activation of the NF-κB pathway, and upregulation of BCL-X L gene expression. Here, we show that TWEAK treatment of glioma cells leads to phosphorylation of Akt and BAD. TWEAK stimulation results in the phosphorylation of both Akt1 and Akt2. However, small interfering RNA (siRNA)-mediated depletion of either Akt1 or Akt2 showed that BAD serine 136 phosphorylation is dependent specifically on Akt2 function. Depletion of Akt2 expression by siRNA also abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival was observed after siRNA-mediated depletion of Akt1 expression. Surprisingly, although siRNA-mediated depletion of BAD in glioma cells abrogates cytotoxic- and chemotherapy-induced apoptosis, TWEAK still displays a strong protective effect, suggesting that BAD serine 136 phosphorylation plays a minor role in TWEAK-Akt2-induced glioma cell survival. We also report here that AKT2 gene expression levels increased with glioma grade and inversely correlate with patient survival. Additionally, immunohistochemical analysis showed that Akt2 expression positively correlates with Fn14 expression in glioblastoma multiforme specimens. We hypothesize that the TWEAK-Fn14 signaling axis functions, in part, to enhance glioblastoma cell survival by activation of the Akt2 serine/threonine protein kinase.

UR - http://www.scopus.com/inward/record.url?scp=72449164564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449164564&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-09-0194

DO - 10.1158/1541-7786.MCR-09-0194

M3 - Article

C2 - 19861406

AN - SCOPUS:72449164564

VL - 7

SP - 1871

EP - 1881

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 11

ER -